The 70th Edition of the British National Formulary has been published. As previously noted, the BNF will now only be distributed annually in the NHS.
Some of the significant content updates in this edition include:
- New safety information about reducing the risk of QT interval prolongation and Torsade de Pointes with hydroxyzine
- New advice about the risk of lymphopenia and potential risk of progressive multifocal leukoencephalopathy with dimethyl fumarate
- Further guidance on the restricted use of codeine for the treatment of cough and cold symptoms in children
- Addition of new indications for omalizumab for treating chronic spontaneous urticaria and for lenalidomide in certain patients with multiple myeloma
- Updated dosing information for the use of tramadol in the treatment of acute and chronic pain
- Guidance about dose reduction for lisdexamfetamine mesilate for patients with severe renal impairment
- Updated contra-indications for aceclofenac in patients with certain established cardiovascular diseases
- Addition of new preparations, including DuoResp Spiromax® (budesonide with formoterol), Envarsus® (tacrolimus), Fostair NEXThaler® (beclometasone with formoterol), Jaydess® (levonorgestrel), Ketoconazole HRA® (ketoconazole) and Lonquex® (lipegfilgrastim)
Action: All clinicians should start using BNF 70 via electronic methods were possible. The web version can be used to access the latest information if necessary.